Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)

Clinical trial NCT03945292 · COMPLETED

Trial details

NCT number: NCT03945292
Sponsor: Arrowhead Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Alpha 1-Antitrypsin Deficiency

Start date: 2019-08-07
Primary completion: 2021-11-08
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.